Results 201 to 210 of about 49,785 (245)

Long‐Term Safety and Efficacy of Pegvaliase in Japanese Adults With Phenylketonuria: Final Results of a Phase III Trial

JIMD Reports, Volume 67, Issue 3, May 2026.
ABSTRACT Phenylketonuria (PKU) is an inborn error of metabolism leading to phenylalanine (Phe) accumulation and consequent neurological, neurocognitive, and psychiatric symptoms. Pegvaliase, a pegylated recombinant phenylalanine ammonia lyase that metabolizes Phe, effectively reduced blood Phe in phase III studies in the United States. This multicenter,
Yoko Nakajima, Mika Ishige, Tetsuya Ito, Takashi Hamazaki, Mitsuhiro Kuwahara, Lawrence Lee, Haruo Shintaku   +6 more
wiley   +1 more source

Chronic Urticaria and Malignancy: A Review Uncovering the Common Links. [PDF]

Biomedicines
Lekli E, Hoxha M, Bova M, Gjonbrataj J, Mati K, Vyshka G, Qirko E.   +6 more
europepmc   +1 more source

Society for Maternal‐Fetal Medicine Special Statement: Assessment and management of reported penicillin allergy in pregnancy

Pregnancy, Volume 2, Issue 3, May 2026.
Abstract Approximately 8% of pregnant people report being allergic to penicillin, yet most of these patients are not truly allergic, either because their allergy has waned or was misdiagnosed in the first place. Penicillin allergy testing can distinguish those who are at risk for reaction to penicillin from those with no or minimal risk.
Society for Maternal‐Fetal Medicine (SMFM), Jennifer Cate, R. Nicholas Burns, Marc Parrish, Alison N. Goulding, Nicole A. Smith, Samuel T. Bauer, Rebecca Hamm, SMFM Patient Safety and Quality Committee   +8 more
wiley   +1 more source

Impact of Seasonal, Environmental, and Inflammatory Factors on Chronic Urticaria Activity and Serum Biomarkers: A Prospective Cohort Study. [PDF]

J Clin Med
Alpagat G, Kalpaklioglu AF, Baccioglu A.
europepmc   +1 more source

Successful Sequential and Additive Drug Challenge With Rapid Oral Desensitization in Rifampicin‐Induced Fever

Respirology Case Reports, Volume 14, Issue 5, May 2026.
We report a 63‐year‐old man with active pulmonary tuberculosis who developed drug‐induced fever after commencing standard anti‐TB therapy. Sequential and additive drug challenge identified rifampicin as the offending agent. The patient subsequently underwent successful rapid oral rifampicin desensitization in an outpatient setting, enabling completion ...
Xin Yue Guo, Constantine Zois
wiley   +1 more source

Vitamin D and Disease Perception Outcomes in a Cluster of Patients with High-Disease-Activity Chronic Spontaneous Urticaria. [PDF]

J Clin Med
Lekli E, Hoxha M, Bova M, Shkëmbi D, Ndreu E, Hajrulla X, Petrela E, Qirko E.   +7 more
europepmc   +1 more source

Occupational Asthma and Contact Urticaria in a Wildlife Worker With Type I Hypersensitivity to Deer Dander

Contact Dermatitis, Volume 94, Issue 6, Page 717-719, June 2026.
Eglė Janušonytė, Thomas Harr, Peter Jandus, Haïg Nigolian   +3 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real‐world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real‐world effectiveness, safety, and treatment persistence of UPA in patients with CD.
M. Iborra, B. Botella, M. D. Martín‐Arranz, D. Ceballos, C. Martínez‐Pascual, A. Garrido, P. Varela, M. Moreta, E. Brunet‐Mas, Y. González‐Lama, E. Rodríguez‐González, M. Vicuña, J. P. Gisbert, I. Ordás, F. Argüelles‐Arias, J. Tosca‐Cuquerella, R. Vicente‐Lidón, M. Sierra‐Ausín, I. Rodríguez‐Lago, D. Martín‐Rodríguez, J. M. Paredes, B. Sicilia, I. García de la Filia, N. Jiménez, M. Barreiro‐de Acosta, E. Betoré, I. Ferrer‐Bradley, L. García‐Alles, J. M. Huguet, S. Castellet‐Farrús, M. J. García, A. Gutiérrez‐Casbas, Á. Ponferrada‐Díaz, L. Ramos, M. Calafat, I. Vera, C. Suárez‐Ferrer, E. Fernández‐Velado, S. Rodríguez‐Sánchez, A. Mínguez, A. Mancebo, J. Barrio, S. Lario, D. R. de La Cruz, Alejandro Hernández‐Camba, C. Rodríguez‐Gutiérrez, M. Chaparro, E. Ricart, L. Almenara‐Michelena, A. Balaguer, E. Domènech, P. Nos   +51 more
wiley   +1 more source

Standardized pressure provocation as an objective clinical marker of omalizumab response in delayed pressure urticaria: an open-label, real-life, prospective cohort. [PDF]

Front Immunol
Konstantinou GN, Podder I.
europepmc   +1 more source